Androgenetic AlopeciaPhase 1/2NCT07429253
Secretome vs. PRP Injections for Hair Density and Growth in Androgenetic Alopecia Patients
A Phase 1/2 study testing Secretome and Platelet-Rich Plasma (PRP) Injections in people with Androgenetic Alopecia, run by PT. Prodia Stem Cell Indonesia at 1 site in Indonesia.
Trial summary
This study aims to compare the effectiveness of secretome injection and intradermal platelet-rich plasma (PRP) injection on hair density and the terminal-to-vellus hair ratio in patients with androgenetic alopecia at Prof. Dr. I.G.N.G. Ngoerah General Hospital. Read more about this study
- Who is it for?
- Ages 25 to 59 years
- Conditions the study is for
- Androgenetic Alopecia
- What is being tested?
- Secretome and Platelet-Rich Plasma (PRP) Injections
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 40 participants
- Where
- 1 siteIndonesia
- Study dates
- 9 Jan 2026to 30 Sep 2026
- Phase
- Phase 1/2
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 25 to 59 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- Male patients with androgenetic alopecia, aged 25 to 59 years, with clinical presentation consistent with Hamilton-Norwood grades II to VI, seeking treatment at the Dermatology and Venereology Outpatient Clinic of Prof. Dr. I.G.N.G. Ngoerah General Hospital.
- Female patients with androgenetic alopecia, aged 25 to 59 years, with clinical presentation consistent with Ludwig grades I to III, seeking treatment at the Dermatology and Venereology Outpatient Clinic of Prof. Dr. I.G.N.G. Ngoerah General Hospital.
- Female patients who are not currently pregnant or breastfeeding.
- Patients who have discontinued anti-androgen medication and minoxidil for at least 1 month prior to the procedure.
- Patients with no known allergies to secretome components and/or materials used in the platelet-rich plasma (PRP) preparation process.
- Patients who are proficient in Indonesian and willing to provide written informed consent.
Who cannot join
- Participants who are unable to speak or understand Indonesian and/or are unwilling to provide written informed consent.
- Patients presenting with types of hair loss other than androgenetic alopecia.
- Patients currently undergoing therapy with 5-alpha reductase inhibitors.
- Patients who have received intradermal corticosteroid injections to the scalp within at least 6 months prior to the study.
- Patients with active infections and/or active dermatitis on the scalp.
- Patients with a known history of allergy to secretome components and/or materials used in the platelet-rich plasma (PRP) preparation process.
- History of hypertrophic scarring or blood clotting (coagulation) disorders.
- Patients unable to complete the research procedures in their entirety.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Indonesia1 site, 1 recruiting
- Recruiting
Prof. dr. I.G.N.G. Ngoerah Central General Hospital
Denpasar, Bali, 80113
Dr. dr. I Gusti Nyoman Darmaputra, Sp.D.V.E., Subsp. O.B.K., FINS, +628124644451, darma@skincentrebali.com
Dr. dr. I Gusti Nyoman Darmaputra, Sp.D.V.E., Subsp. O.B.K., FINS
About this study
Official title: Comparative Effectiveness of Secretome Injection and Intradermal Platelet-Rich Plasma Injection on Hair Density and Terminal-to-Vellus Hair Ratio in Patients With Androgenetic Alopecia at Prof. Dr. I.G.N.G. Ngoerah General Hospital
This study aims to compare the effectiveness of secretome injection and intradermal platelet-rich plasma (PRP) injection on hair density and the terminal-to-vellus hair ratio in patients with androgenetic alopecia at Prof. Dr. I.G.N.G. Ngoerah General Hospital.
Read the detailed description
This research is an experimental study with a randomized controlled clinical design involving two intervention groups: one receiving secretome injections and the other receiving intradermal platelet-rich plasma injections. Evaluations are conducted by measuring hair density and the terminal-to-vellus hair ratio before and after treatment using trichoscopy/dermoscopy.
- Conditions
- Androgenetic Alopecia
- Being tested
- Secretome, Platelet-Rich Plasma (PRP) Injections
- Keywords
- Secretome, Platelet-Rich Plasma, Androgenetic Alopecia, Trichoscopy
- Medical subject headings
- Alopecia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
SecretomeBiological
UC-MSC secretome was injected intradermally into the scalp at the alopecia site, with injections spaced 1 cm apart and administered every 2 weeks for 8 weeks
Platelet-Rich Plasma (PRP) InjectionsBiological
The centrifuged plasma solution was injected intradermally into the scalp at the alopecia site, with 0.1 ml per injection point spaced 1 cm apart, administered every 2 weeks for 8 weeks
| Study group | Role | What they receive |
|---|---|---|
| UC-MSC Secretome | Experimental | Umbilical Cord Mesenchymal Stem Cell-derived Secretome Receives: Biological: Secretome |
| Platelet-Rich Plasma | Experimental | Platelet-Rich Plasma Receives: Biological: Platelet-Rich Plasma (PRP) Injections |
What is being measured
The primary outcome is the main question the study is designed to answer.
Terminal-to-Vellus Hair Ratio
The ratio of terminal hair (thick, pigmented hair, diameter >40 micrometer) to vellus hair (fine hair, diameter <30 micrometer) in areas of androgenetic alopecia
Measured: Baseline (before treatment), post-intervention (at 8 weeks), and during follow-up visits (months 3, 6, and 9)
Hair density
The number of hairs per specific scalp area was measured in hairs/cm²
Measured: Baseline (before treatment), post-intervention (at 8 weeks), and during follow-up visits (months 3, 6, and 9)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Feb 2026
- Study start9 Jan 2026
- Primary completion30 Jun 2026 (estimated)
- Study completion30 Sep 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Androgenetic AlopeciaStudies of the same condition, open and under way.
- More trials run by PT. Prodia Stem Cell IndonesiaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1/2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 40 participants (estimated)
Sponsor and investigators
- Lead sponsor
- PT. Prodia Stem Cell Indonesia
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- RSUP Prof. Dr. I.G.N.G. Ngoerahal
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07429253
- Sponsor's protocol ID
- CT/ALP/02/2025
- Status last verified
- Feb 2026
- First submitted
- 17 Feb 2026
- Last updated
- 24 Feb 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 24 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Comparative Effectiveness of Secretome Injection and Intradermal Platelet-Rich Plasma Injection on Hair Density and Terminal-to-Vellus Hair Ratio in Patients With Androgenetic Alopecia at Prof. Dr. I.G.N.G. Ngoerah General Hospital
- ClinicalTrials.gov ID
- NCT07429253
- Acronym / sponsor ID
- CT/ALP/02/2025
- Conditions
- Androgenetic Alopecia
- Keywords
- Secretome, Platelet-Rich Plasma, Androgenetic Alopecia, Trichoscopy
- Phase
- Phase 1/2
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 40 participants (estimated)
- Lead sponsor
- PT. Prodia Stem Cell IndonesiaIndustry (pharma, biotech, devices)
- Collaborators
- RSUP Prof. Dr. I.G.N.G. Ngoerahal
- Study start
- 9 Jan 2026 (actual)
- Primary completion
- 30 Jun 2026 (estimated)
- Study completion
- 30 Sep 2026 (estimated)
- First posted
- 24 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aims to compare the effectiveness of secretome injection and intradermal platelet-rich plasma (PRP) injection on hair density and the terminal-to-vellus hair ratio in patients with androgenetic alopecia at Prof. Dr. I.G.N.G. Ngoerah General Hospital.
Detailed description
This research is an experimental study with a randomized controlled clinical design involving two intervention groups: one receiving secretome injections and the other receiving intradermal platelet-rich plasma injections. Evaluations are conducted by measuring hair density and the terminal-to-vellus hair ratio before and after treatment using trichoscopy/dermoscopy.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| UC-MSC Secretome | Experimental | Biological: SecretomeUmbilical Cord Mesenchymal Stem Cell-derived Secretome |
| Platelet-Rich Plasma | Experimental | Biological: Platelet-Rich Plasma (PRP) InjectionsPlatelet-Rich Plasma |
Who may qualify
- Ages
- 25 to 59 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (6 listed)
- Male patients with androgenetic alopecia, aged 25 to 59 years, with clinical presentation consistent with Hamilton-Norwood grades II to VI, seeking treatment at the Dermatology and Venereology Outpatient Clinic of Prof. Dr. I.G.N.G. Ngoerah General Hospital.
- Female patients with androgenetic alopecia, aged 25 to 59 years, with clinical presentation consistent with Ludwig grades I to III, seeking treatment at the Dermatology and Venereology Outpatient Clinic of Prof. Dr. I.G.N.G. Ngoerah General Hospital.
- Female patients who are not currently pregnant or breastfeeding.
- Patients who have discontinued anti-androgen medication and minoxidil for at least 1 month prior to the procedure.
- Patients with no known allergies to secretome components and/or materials used in the platelet-rich plasma (PRP) preparation process.
Key exclusion criteria (8 listed)
- Participants who are unable to speak or understand Indonesian and/or are unwilling to provide written informed consent.
- Patients presenting with types of hair loss other than androgenetic alopecia.
- Patients currently undergoing therapy with 5-alpha reductase inhibitors.
- Patients who have received intradermal corticosteroid injections to the scalp within at least 6 months prior to the study.
- Patients with active infections and/or active dermatitis on the scalp.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| SecretomeUC-MSC secretome was injected intradermally into the scalp at the alopecia site, with injections spaced 1 cm apart and administered every 2 weeks for 8 weeks | Biological | UC-MSC Secretome |
| Platelet-Rich Plasma (PRP) InjectionsThe centrifuged plasma solution was injected intradermally into the scalp at the alopecia site, with 0.1 ml per injection point spaced 1 cm apart, administered every 2 weeks for 8 weeks | Biological | Platelet-Rich Plasma |
Primary outcome
Terminal-to-Vellus Hair Ratio
Time frame: Baseline (before treatment), post-intervention (at 8 weeks), and during follow-up visits (months 3, 6, and 9)
The ratio of terminal hair (thick, pigmented hair, diameter >40 micrometer) to vellus hair (fine hair, diameter <30 micrometer) in areas of androgenetic alopecia
Hair density
Time frame: Baseline (before treatment), post-intervention (at 8 weeks), and during follow-up visits (months 3, 6, and 9)
The number of hairs per specific scalp area was measured in hairs/cm²
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Feb 2026.
- Individual participant dataSharing planned: No
Related trials for Androgenetic Alopecia
Not yet recruitingPhase 2
Phase 2 Efficacy and Safety of PP405 in Adult Females With Androgenetic Alopecia
Androgenetic Alopecia
Not yet recruitingPhase 3
Phase 3 Study to Evaluate the Efficacy and Safety of Oral Minoxidil (N1087) in Men With Androgenetic Alopecia.
Androgenetic Alopecia, Androgenetic Alopecia (AGA)
Not yet recruiting
Study to Evaluate Xtressé Gummy Supplement in Women With Thinning Hair
Androgenetic Alopecia
Not yet recruitingEarly Phase 1
Evaluating the Efficacy of Platelet-rich Plasma Therapy in the Treatment of Androgenic Alopecia
Androgenic Alopecia
Not yet recruitingPhase 3
Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of N1087 in Participants With Female Pattern Hair Loss (MINORA-WOMEN)
Female Pattern Hair Loss, Female Pattern Hair Loss, Androgenic Alopecia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Prof. dr. I.G.N.G. Ngoerah Central General Hospital
Denpasar, Indonesia
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1/2 study testing Secretome and Platelet-Rich Plasma (PRP) Injections in people with Androgenetic Alopecia, run by PT. Prodia Stem Cell Indonesia at 1 site in Indonesia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 24 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Indonesia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this combined phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Terminal-to-Vellus Hair Ratio (time frame: Baseline (before treatment), post-intervention (at 8 weeks), and during follow-up visits (months 3, 6, and 9)). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Feb 2026.